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Definition of Arrhythmia 
 
   Cardiac arrhythmia (also dysrhythmia) 
is a term for any of a large and 
heterogeneous group of conditions in 
which there is abnormal electrical 
activity in the heart.  
That is the Origin, Rate, Rhythm, 
Conduct velocity and/or sequence of 
heart activation are abnormal. 
Normal electrical activity in the heart  
Each heart beat originates as an 
electrical impulse from a small 
area of tissue in the right atrium of 
the heart called the sinus node or 
Sino-atrial node or SA node. The 
impulse initially causes both of the 
atria to contract, then activates 
the atrioventricular (or AV) node 
which is normally the only 
electrical connection between the 
atria and the ventricles , which 
can be called as main pumping 
chambers.  
The impulse then spreads through both ventricles via the Bundle of His 
and the Purkinje fibres causing a synchronised contraction of the 
heart muscle, and thus, the pulse 
Sinus Rhythm Criteria: 
1. Every QRS complex is preceded by a P-wave 
 
2. P-waves appear normal, that is they are of sinus node 
origin: 
 
  A.  Normal Morphology: 
   1.  P-wave duration < 0.12 sec 
   2.  P-wave height < 2.5 mm  
 
  B.  Normal Axis: 
   1.  P-waves is upright in leads II, III & aVF 
   2.  P-waves is negative in lead aVR 
Etiology of  Arrhythmias  
• Congenital - Present at birth due to 
genetics, or conditions during the peri-
natal environment  
• Violations of neurohumoral (including 
endocrine) regulation of the heart 
(disregulatory arrhythmias) 
• Organic (congenital and acquired) 
heart defects 
• Other system disease  
• Electrolyte disturbance and acid-base 
imbalance  
• Drugs, toxic and chemical substances  
• Unknown origin 
 
Mechanisms of Arrhythmia 
•  reentry (most common) 
•  automaticity 
•  triggered activity 
Fast Conduction Path 
Slow Recovery 
Slow Conduction Path 
Fast Recovery 
Reentry Requires… 
Electrical Impulse 
Cardiac 
Conduction 
Tissue 
1. 2 distinct pathways that come together at 
beginning and end to form a loop.   
2. A unidirectional block in one of those pathways.   
3. Slow conduction in the unblocked pathway.    
Fast Conduction Path 
Slow Recovery 
Slow Conduction Path 
Fast Recovery 
Premature Beat Impulse 
Cardiac 
Conduction 
Tissue 
1.  An arrhythmia is triggered by a premature beat  
2.  The fast conducting pathway is blocked because of its 
long refractory period so the beat can only go down the 
slow conducting pathway 
Repolarizing Tissue 
(long refractory period) 
Reentry Mechanism 
3.  The wave of excitation from the premature beat 
arrives at the distal end of the fast conducting 
pathway, which has now recovered and therefore 
travels retrogradely (backwards) up the fast pathway  
Fast Conduction Path 
Slow Recovery 
Slow Conduction Path 
Fast Recovery 
Cardiac 
Conduction 
Tissue 
Reentry Mechanism 
4.  On arriving at the top of the fast pathway it finds the 
slow pathway has recovered and therefore the wave of 
excitation ‗re-enters‘ the pathway and continues in a 
‗circular‘ movement.  This creates the re-entry circuit 
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Atrial Reentry 
• atrial tachycardia 
• atrial fibrillation 
• atrial flutter 
Atrio-Ventricular 
Reentry 
• WPW 
• SVT 
Ventricular Re-entry 
• ventricular tachycardia 
AV Nodal Reentry 
•SVT 
Reentry Circuits 
SA Node 
Reentry Requires… 
1. 2 distinct pathways that come together at 
beginning and end to form a loop.   
2. A unidirectional block in one of those pathways.   
3. Slow conduction in the unblocked pathway.    
Large reentry circuits, like a-flutter, involve the 
atrium.   
Reentry in WPW involves atrium, AV node, 
ventricle and accessory pathways. 
Terminating Reentry 
• Spontaneous termination  
–Another premature beat that disturbs the 
underlying conduction/refractoriness 
relationships 
• Pace the heart at a rate above the 
tachycardia rate 
–Abruptly stop pacing 
–This is how implantable cardioverter-
defibrillators can stop VT without a shock 
(ATP) 
Automaticity 
•  Heart cells other than those of the SA 
node depolarize faster than SA node 
cells, and take control as the cardiac 
pacemaker.   
•  Factors that enhance automaticity 
include:  
 SANS,  PANS,  CO2,  O2,  H
+,  
stretch, hypokalemia and hypocalcaemia.   
Examples:  ventricular ectopy after MI 
Mechanisms of Rhythm Disorders  
Triggered Activity 
Early Afterdepolarization arise during 
the plateau phase (2) or the 
repolarization phase (3) of the last 
beat: 
 - Low potassium blood levels 
 - Slow heart rate 
 - Drug toxicity (ex. Quinidine causing 
   Torsades de Pointes type of VT) 
  
 
Late Afterdepolarization arise during 
the resting phase (4) of the last beat  
•   Potential Causes: 
    -  Premature beats 
    -  Increased calcium blood levels 
    -  Increased adrenaline levels 
    -  Digitalis toxicity 
 
Depolarization occurring in Phase 3 
(2) or 4 of the action potential can 
trigger arrhythmias 
Diagnosis of Arrhythmia 
Interviewing (irregular, rapid heart beats, shortness of 
breath, palpitation, fainting) 
Physical examination (rhythm abnormalities, signs of 
underlying cardiac or non-cardiac disease) 
Lab tests- usual + electrolytes (K, Na), thyroid function 
Echocardiography (structural heart diseases, LV EF) 
ECG; Holter ECG monitoring  
Stress tests ("sit-stand ―,  a test with 20 squats, bicycle 
ergometry, treadmill test, isometric test (hand, foot) 
Transesophageal electrical cardiostimulation 
Psychoemotional tests  
Event Monitors 
 Holter monitoring:  Document symptomatic and 
asymptomatic arrhythmias over 24-48 hours.  
Can also evaluate treatment effectiveness in a-
fib, pacemaker effectiveness and identify silent 
MIs.   
 Trans-telephonic event recording:  patient either 
wears monitor for several days or attaches it 
during symptomatic events and an ECG is 
recorded and transmitted for evaluation via 
telephone.  Only 20% are positive, but still 
helpful. 
Exercise testing 
•  Symptoms only appear or worsen with 
exercise.  
• Premature ventricular contractions (PVCs) 
occur in 10% without and 60% of patients 
with CAD.  PVCs DO NOT predict severity of 
CAD (neither for nor against)!  
•  Also used to evaluate medication 
effectiveness (esp. flecanide & propafenone)   
You can assess SA node function with exercise testing. 
* 
Electrophysiologic Testing… 
•  Catheters are placed in RA, AV node, Bundle of 
HIS, right ventricle, and coronary sinus (to 
monitor LA and LV).   
•  Used to evaluate cardiogenic syncope of 
unknown origin, symptomatic SVT, symptomatic 
WPW, and sustained v-tach.   
*Ablative therapy is beneficial in AV node reentry, 
WPW, atrial tachycardia, a-flutter, and some v-
tach.  Complication is 1% 
Therapy Principal 
• Pathogenesis therapy – treatment 
underlying condition 
• Stop the arrhythmia immediately  if the 
hemodynamic was unstable 
• Individual therapy 
Anti-arrhythmia Agents 
• Anti-tachycardia agents 
• Anti-bradycardia agents 
Anti-bradycardia agents 
• ß-adrenic receptor activator 
(epinephrine, adrenaline, isoprenaline) 
• M-cholinergic receptor blocker 
(Atropine) 
• Non-specific activator (Aminophylline) 
Anti-tachycardia agents 
Modified Vaugham Williams classification 
1. I class: Natrium channel blocker 
2. II class: ß-receptor blocker 
3. III class: Potassium channel blocker 
4. IV class: Calcium channel blocker 
5. Others: Adenosine, Digital 
Class 1A agents:  Procainamide, Quinidine, 
Disopyramide 
   
Uses 
Wide spectrum, but side effects limit usage 
 
Quinidine : maintain sinus rhythms in atrial fibrillation and flutter 
and to prevent recurrent tachycardia and fibrillation      
 
Procainamide: acute treatment of supraventricular and 
ventricular arrhythmias (no longer in production) 
Disopyramide: treat certain types of serious (possibly 
fatal)ventricular arrhythmias 
Side effects 
 Hypotension, reduced cardiac output 
 Proarrhythmia (generation of a new arrhythmia) eg.   
 Torsades de Points (QT interval) 
              Dizziness, confusion, insomnia, seizure (high dose) 
              Gastrointestinal effects (common) 
              Lupus-like syndrome (esp. procainamide) 
 
Class 1B agents:  Lidocaine, 
Phenytoin, Mexiletine 
 
 
 
Uses 
 acute : Ventricular tachycardia and fibrillation (esp. 
during   ischemia) 
 
 Not used in atrial arrhythmias or AV junctional 
arrhythmias 
      
 Side effects  
                Less proarrhythmic than Class 1A (less QT effect) 
                CNS effects: dizziness, drowsiness 
 
Class 1C agents:  Flecainide, 
Propafenone 
 
Uses 
 Wide spectrum 
 Used for supraventricular arrhythmias (fibrillation and 
        flutter) 
              Premature ventricular contractions (caused problems) 
  Wolff-Parkenson-White syndrome 
 
Side effects 
 Proarrhythmia and sudden death especially with chronic 
       use  (CAST study)  
 Increase ventricular response to supraventricular  
       arrhythmias 
 CNS and gastrointestinal effects like other local  
        anesthetics 
Class II agents:  Beta-blockers 
 
 
Uses 
 treating sinus and catecholamine dependent tachy  
     arrhythmias 
 
 converting reentrant arrhythmias in AV 
  
 protecting the ventricles from high atrial rates (slow AV 
       conduction) 
 
Side effects 
          bronchospasm 
             hypotension 
              beware in partial AV block or ventricular failure 
 
Class III agents:  Amiodarone, Sotalol, 
Ibutilide 
 
Amiodarone 
 
Uses 
 Very wide spectrum: effective for most arrhythmias 
 
Side effects: many serious that increase with time 
 Pulmonary fibrosis 
 Hepatic injury 
             QT prolongation 
 Increase LDL cholesterol 
 Thyroid disease 
 Photosensitivity 
 
May need to reduce the dose of digoxin and class 1 antiarrhythmics 
Class III agents:  Amiodarone, Sotalol, 
Ibutilide 
 
Sotalol 
 
Uses 
  Wide spectrum: supraventricular and ventricular tachycardia 
                    
Side effects 
   Proarrhythmia,  
             fatigue, 
             insomnia 
Contraindicated in systolic ventricular dysfunction 
 
 
Class III agents:  Amiodarone, 
Sotalol, Ibutilide 
 
Ibutilide 
 
Uses 
 conversion of atrial fibrillation and flutter with rapid IV 
infusion 
            
Side effects 
 Torsades de pointes 
 
Class IV agents:  Verapamil and 
Diltiazem 
 
 
 
Uses 
 control ventricular rate during supraventricular 
tachycardia 
  
 convert supraventricular tachycardia (re-entry around 
AV) 
 
Side effects 
 Caution when partial AV block is present.  
             Can get asystole if β blocker is on board 
Caution when hypotension, decreased CO or sick sinus  
syndrome 
Some gastrointestinal problems 
 
Additional agents 
 
Adenosine 
Administration                      
 rapid i.v. bolus, very short T1/2 (seconds) 
  
Cardiac effects 
 Slows AV conduction 
 
Uses 
 convert re-entrant supraventricular arrhythmias 
 hypotension during surgery, diagnosis of CAD 
 
Magnesium 
Torsades de point from any reason 
Arrhythmias in a patient with known hypomagnesaemia. 
Consider its use in acute ischaemia to prevent early ventricular 
arrhythmias. 
 Digoxin induced arrhythmias 
 
Proarrhythmia effect of 
antiarrhythmia agents 
• Ia, Ic class: Prolong QT interval, may 
cause VT or VF in coronary artery 
disease and heart failure patients 
• III class: Like Ia, Ic class agents 
• II, IV class: Bradycardia 
 
Non-drug therapy 
• Cardioversion: For tachycardia 
especially hemodynamic unstable patient 
• Radiofrequency catheter ablation (RFCA): 
For those tachycardia patients (SVT, VT, 
AF, AFL) 
• Artificial cardiac pacing: For bradycardia, 
heart failure and malignant ventricular 
arrhythmia patients. 
Violations of automaticity 
• Nomotopic (pacemaker - in the sinus node) 
– sinus tachycardia (ST) 
– sinus bradycardia (SB) 
– sinus arrhythmia (SA) 
– sick sinus syndrome (SSS) 
• Heterotopic (pacemaker - outside the sinus 
node) 
– atrial rhythm 
– atrioventricular rhythm 
– idioventricular rhythm  
Classification of arrhythmias 
Violations of excitability 
• Premature complex 
– by site: atrial, atrioventricular, ventricular 
– according to the number of sources: monotopic, 
politopic 
– according to time of occurrence: early interpolated, 
late 
– according to frequency: single (up to 5 per minute), 
multiple (more than 5 per minute), pair (couplet) 
– According to ordering: unordered, allorythmias 
(bigeminy, trigeminy, quadrigeminy) 
• Paroxysmal tachycardia (atrial, AV, ventricular)  
Classification of arrhythmias 
Conduction abnormalities 
– The increase in conductivity (Wolff-Parkinson 
White (WPW) syndrome) 
– The decrease in conductivity (blockade: 
sinoauricular, intraatrial, AV, bundle-branch 
block) 
• Mixed (atrial / ventricular    flutter / 
fibrillation )  
Classification of arrhythmias 
Sinus tachycardia  
Sinus rate > 100 beats/min (100-180) 
Causes: 
1. Some physical condition: exercise, anxiety, exciting, 
alcohol, coffee 
2. Some disease: fever, hyperthyroidism, anemia, myocarditis  
3. Some drugs: Atropine, Isoprenaline  
Clinical significance: 
Benign  and needn‘t therapy in most cases 
But sometimes:  
• Dizziness and hypotension due  to decreased CO 
• Increased myocardial oxygen consumption may lead to angina 
Treatment : address underlying cause and/or determining if it is 
even a problem (adenosine, beta blockers). 
 
Sinus Bradycardia 
Sinus rate < 60 beats/min  
Normal variant in many normal and older people 
Causes:  Cause-vagal stimulation, athlete, during sleep, drugs (Beta 
blockers;  digoxin), head injuries, MI, hypothyriodism, 
Clinical significance- Dependent on symptoms 
Most patients have no symptoms. 
Severe bradycardia may cause dizziness, confusion or 
disorientation, shortness of breath, fatigue, palpitation, even 
syncope.  
Needn‘t specific therapy 
If the patient has severe symptoms, atropine or planted an 
pacemaker may be needed.  
• Rate 60-100 
• Irregular rhythm- increases with inspiration, 
decreases with expiration 
• P, QRS,T wave normal 
• Cause- children, myocardial ischemia 
• Treatment- none (underlying condition) 
Sinus Arhythmia 
Sinus Arrest 
• See pauses 
• May see ectopic beats (PAC’s PVC’s) do 
not treat 
• Cause myocardial ischemia 
• Treatment 
– Atropine 
– Isoprenaline 
–  Pacemaker  
Sinus Arrest or Sinus 
Standstill 
• Sinus arrest or standstill is recognized by a pause 
in the sinus rhythm.  
• Causes:  myocardial ischemia, hypoxia, 
hyperkalemia, higher intracranial pressure, sinus 
node degeneration and some drugs (digitalis, ß-
blocks). 
• Symptoms: dizziness, amaurosis, syncope 
• Therapy – atropine, pacemaker 
Pause ≠ n x PP 
PP 
Pause 
Sick Sinus Syndrome (SSS) 
• SSS: The function of sinus node was 
degenerated. SSS encompasses both 
disordered SA node automaticity and SA 
conduction. 
• Causes: CAD, SN degeneration, myopathy, 
connective tissue disease, metabolic disease, 
tumor, trauma and congenital disease. 
• With marked sinus bradycardia, sinus arrest, 
sinus exit block or junctional escape rhythms 
• Bradycardia-tachycardia syndrome    
Sick Sinus Syndrome (SSS) 
ECG Recognition: 
1. Sinus bradycardia ≤40 bpm;  
2. Sinus arrest (pauses > 3s) 
3. Type II SAB 
4. Nonsinus tachyarrhythmia ( SVT, AF 
or Af). 
 

Sick Sinus Syndrome (SSS) 
Therapy: 
1. Treat the etiology 
2. Treat with drugs: anti-bradycardia 
agents, the effect of drug therapy is 
not good. 
3. Artificial cardiac pacing. 
Premature contractions 
• The term ―premature contractions‖ 
are used to describe non sinus beats.  
• Common arrhythmia 
• The morbidity rate is 3-5% 
 
Atrial premature contractions (APCs) 
• APCs arising from somewhere in either the left 
or the right atrium. 
• ECG:  P wave abnormally shaped, PR interval 
shorter, QRS normal, incomplete compensatory 
pause 
A-V premature contractions  
With simultaneous excitation of the atria and ventricles 
ECG signs: 
- P wave is not determined 
- premature QRS complex is not expanded 
- Incomplete compensatory pause 
With preceding by excitation of the ventricles 
ECG signs: 
- P wave after QRS 
     - premature QRS complex is not expanded 
- complete compensatory pause 
 
Atrial and A-V premature 
contractions 
• Causes: may occur in normal person, 
smoking. caffeine, rheumatic heart disease, 
CAD, hypertension, hyperthyroidism, 
hypokalemia 
• Symptoms: many patients have no 
symptom, some have palpitation, chest 
incomfortable. 
• Therapy: Needn‘t therapy in the patients 
without heart disease. Can be treated with 
ß-blocker, propafenone? or verapamil (watch 
for SVT). 
 
Ventricular Premature 
Contractions (VPCs) 
Etiology: 
1. Occur in normal person 
2. Myocarditis, CAD, valve heart disease, 
hyperthyroidism, Drug toxicity 
(digoxin, quinidine and anti-anxiety 
drug) 
3. Electrolyte disturbance, anxiety, 
drinking, coffee 
Premature Ventricular 
Contractions 
• Clinical significance 
– In normal heart, usually benign 
– In heart disease, PVCs may decrease CO 
and precipitate angina and HF  
• **Patient’s response to PVCs must be 
monitored  
• PVCs often do not generate a sufficient 
ventricular contraction to result in a 
peripheral pulse, so apical-radial pulse rate 
should be assessed to determine if pulse 
deficit exists  
Premature Ventricular 
Contractions (PVC’s)-ectopic 
• QRS wide and bizarre 
•  no P waves 
• T opposite deflection of PVC 
• complete compensatory pause 
 
PVC’s 
•    
 
Multifocal- from more than one foci 
Bigeminy- every other beat is a PVC 
 trigeminy- every third beat is a PVC 
Couplet- 2 PVC’s in a row 
PVC’s multi-focal PVC’s uni-focal 
Treat if: 
• >5 PVC’s a minute 
• Runs of PVC’s (≥3 
PVC’s) 
• Multi focal PVC’s 
• “R on T”   
 
 
PVCs: Treatment 
Therapy: treat underlying disease, antiarrhythmia 
• No structure heart disease:  
antianxiety agents, ß-blocker and mexiletine to relief the 
symptom. 
• With structure heart disease (CAD, LVH): 
1. Treat the underlying disease 
2. ß-blocker, amiodarone 
3. Class I especially class Ic agents should be avoided 
because of proarrhytmia and lack of benefit of prophylaxis 
Supraventricular Tachycardia 
(SVT)/PSVT (paroxysmal SVT) 
• Rate- 150-250 (Very fast!) 
• Atria is pacemaker (may not see p waves) 
• Cause-SNS stimulation, MI, CHF, sepsis  
• Treatment- adenosine, digoxin, calcium channel 
blockers, beta-blockers, vagal stimulation 
Atrial flutter 
Etiology: 
1. It can occur in patients with normal 
atrial or with abnormal atrial. 
2. It is seen in rheumatic heart disease 
(mitral or tricuspid valve disease), 
CAD, hypertension, hyperthyroidism, 
congenital heart disease, COPD.  
3. Related to enlargement of the atria 
4. Most AF have a reentry loop in right 
atrial 
Rate of atria is 250-300, vent rate varies 
P waves saw tooth, ratio 2:1, 3:1, 4:1 
Flutter waves- No PR interval 
Atrial flutter 
Symptoms: depend on underlying 
disease, ventricular rate, the patient is 
at rest or is exerting  
• With rapid ventricular rate: palpitation, 
dizziness, shortness of breath, 
weakness, faintness, syncope, may 
develop angina and CHF. 
Atrial flutter 
Therapy: 
1. Treat the underlying disease 
2. To restore sinus rhythm: Cardioversion, 
Esophageal Pulsation Modulation, 
radiofrequency catheter ablation (RFCA) of 
the AV junction , Drug (III, Ia, Ic class). 
3. Control the ventricular rate: digitalis,  CCB, 
ß-block 
4. Anticoagulation (as in atrial fibrillation) 
Atrial fibrillation 
Chaotic atrial rhythm due to multiple reentrant 
wavelets, 350-500 bpm 
Ventricular rate irregular and rapid due to variable 
AV block 
Etiology: 
1. Morbidity rate increase in older patients 
2. Etiology just like atrial flutter 
3. Idiopathic 
Mechanism:  
1. Multiple wavelet re-entry; 
2. Rapid firing focus in pulmonary vein, vena 
cava or coronary sinus. 

Classification of atrial fibrillation 
(AF) 
1. First diagnosed AF  - every patient who 
presents with AF for the first time, 
irrespective of the duration of the arrhythmia 
or the presence and severity of AF-related 
symptoms. 
2. Paroxysmal AF is self-terminating, usually 
within 48 h. Although AF paroxysms may 
continue for up to 7 days, the 48 h time point 
is clinically important—after this the 
likelihood of spontaneous conversion is low 
and anticoagulation must be considered. 
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Classification of atrial fibrillation 
(AF) 
3. Persistent AF -  is present when an AF 
episode either lasts longer than 7 days or 
requires termination by cardioversion, either 
with drugs or by direct current cardioversion 
(DCC). 
4. Long-standing persistent AF has lasted for 
≥1 year when it is decided to adopt a rhythm 
control strategy. 
5. Permanent AF  -  when the presence of the 
arrhythmia is accepted by the patient (and 
physician).  
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Atrial fibrillation 
Manifestation: 
• Affected by underlying diseases, ventricular rate 
and heart function.  
• May develop embolism in left atrial. Have high 
incidence of stroke. 
• The heart rate, S1 and rhythm is irregularly 
irregular 
Atrial fibrillation 
Therapy: 
1. Treat the underlying disease 
2. Restore sinus rhythm: Drug, 
Cardioversion, RFCA 
3. Rate control: digitalis. CCB, ß-block 
4. Antithrombotic therapy: Aspirine, 
Warfarin (INR 2.0–3.0) 
 
    
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Rate control 

The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Treatment of atrial fibrillation: maintaining 
sinus rhythm 
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Identifying the risk of 
thromboembolic complications 
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Approach to thromboprophylaxis in 
patients with AF 
The Task Force for the Management of Atrial Fibrillation of the ESC, 2010 
Atrial Fibrillation 
Catheter Ablation 
Ablate PV potentials           PV Isolation                Pappone 
                 (circumferential LA ablation) 
Ventricular tachycardia 
• Etiology: often in organic heart disease  
   CAD, MI, DCM, HCM, HF, long QT 
syndrome 
• Sustained VT (>30s), Nonsustained VT 
• Monomorphic VT, Polymorphic VT 
ECG in ventricular tachycardia: 
ventricular rate 150-250, regular or irregular 
no P waves 
QRS>0.12 msec 
VT 
Manifestation:  
1. Nonsustained VT with no symptom    
2. Sustained VT : with symptom and 
unstable hemodynamic, patient 
may feel palpitation, short of 
breathness, presyncope, syncope, 
angina, hypotension and shock. 
Treatment of VT 
1. Treat underlying disease 
2. Cardioversion: Hemodynamic 
unstable VT (hypotension, shock, 
angina, CHF) or hemodynamic 
stable but drug was no effect 
3. Pharmacological therapy: ß-
blockers, lidocain or amiodarone 
4. RFCA, ICD or surgical therapy 
Medtronic Implantable Defibrillators (1989-1997)
209 cc 113 cc
80 cc 72 cc 54 cc
71 mm x 58 mm x 16 mm
2 4/5 in  x 2 1/3 in x 2/3 in
80 cc
Implanatable defibrillators 
Implanatable defibrillator in-situ 
Ventricular tachycardia 
Torsades de points (Tdp): A special type of 
polymorphic VT 
Etiology:  
1. congenital (Long QT),  
2. electrolyte disturbance: hypo/hyperkalemia, 
HYPOMAGNESEMIA 
3. antiarrhythmia drug proarrhythmia (IA or IC), 
antianxiety drug, antimicrobial drugs 
(acquired long QT-syndrome),  
4. brain disease 
Treatment - includes treating cause(s), 
medications (magnesium) , and 
defibrillation or cardioversion. 
VT- Torsades de Pointes 
French for twisting of the points 
  
Ventricular flutter and fibrillation 
• Often occur in severe organic heart 
disease: AMI, ischemia heart disease 
• Proarrhythmia (especially produce long 
QT and Tdp), electrolyte disturbance 
• Anaesthesia, electric shock, heart 
operation 
• It‘s a fatal arrhythmia 

Ventricular flutter and fibrillation 
Manifestation: 
     Unconsciousness, twitch, no blood 
pressure and pulse, going to die 
Therapy: 
Cardio-Pulmonary Resuscitate (CPR) 
ICD 
